Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
Analysis
Comment
Deals
Events
News
People

Flotation

Lemonade demonstrates $319m flotation
SoftBank, XL Catlin, Allianz and Alphabet-backed casualty and property isnurance provider Lemonade priced the initial public offering above its range.
Shift gears up for reverse merger
The Lithia Motors, BMW and Alliance Ventures-backed automotive e-commerce marketplace is set to go public through a reverse merger with Insurance Acquisition.
Pandion plans $75m initial public offering
SR One and Roche Venture Fund-backed Pandion Therapeutics will use the proceeds from the offering to advance a lead drug candidate for ulcerative colitis.
Akouos acquires $213m in initial public offering
The hearing loss treatment developer, which counts Novartis Venture Fund and Partners Innovation Fund as investors, floated above its range.
Fusion Pharma fetches $213m in IPO
Johnson & Johnson and Varian Medical exited the cancer radiotherapy developer in an upsized initial public offering after $158m in funding.
Agora accomplishes $350m flotation
The SIG-backed video communication software provider priced its shares above the range and will go public later today.
Forma Therapeutics finishes IPO at $319m
Forma Therapeutics, whose investors include Eli Lilly and Novartis, has closed its IPO after seeing its shares double in price.
Repare rounds off $253m initial public offering
Celgene Switzerland and BMS-backed precision cancer drug developer Repare Therapeutics added $33m to its IPO after its shares rose 65% post-offering.

Other News

Genetron jumps to public markets in $256m IPO
Vcanbio scored an exit as the precision cancer treatment and diagnostics developer went public in an upsized offering priced well above its range.
Forma forces its way to $278m IPO
The Novartis and Eli Lilly-backed cancer and haematologic disease drug developer will go public today having expanded the size of its offering.
Repare reaches public markets with $220m
The targeted oncology drug developer, which counts Bristol Myers Squibb and Celgene as investors, is floating above its range in an upsized offering.
Kangua canters to $149m IPO
Rabies and meningities vaccine producer Kanghua Biological, which counts Aokang and Tigermed as investors, has floated in its home country of China.
Burning Rock blazes a trail on to public markets
The Legend Holdings and Eli Lilly-backed cancer diagnostics technology developer floated above its range to raise $223m and its shares have since risen 40%.
Vaxcyte racks up $250m in IPO
Vaccine developer Vaxcyte has floated in an upsized initial public offering having raised $110m in a Roche-backed round just three months ago.

Editor's Picks

Lemonade demonstrates $319m flotation
SoftBank, XL Catlin, Allianz and Alphabet-backed casualty and property isnurance provider Lemonade priced the initial public offering above its range.
Forma Therapeutics finishes IPO at $319m
Forma Therapeutics, whose investors include Eli Lilly and Novartis, has closed its IPO after seeing its shares double in price.
Forma forces its way to $278m IPO
The Novartis and Eli Lilly-backed cancer and haematologic disease drug developer will go public today having expanded the size of its offering.
Avidity achieves $259m initial public offering
Muscle disease drug developer Avidity, which counts Eli Lilly, EMS, Takeda and ST Pharm as investors, went public in a significantly upized IPO.
test reg

Login